| Literature DB >> 29710849 |
Kaihong Yan1,2, Ravi Naidu3,4, Yanju Liu5,6, Ayanka Wijayawardena7,8, Luchun Duan9,10, Zhaomin Dong11,12.
Abstract
Chronic exposure to arsenic (As) is a global concern due to worldwide exposure and adverse effects, and the importance of incorporating bioavailability in the exposure assessment and risk assessment of As is increasing acknowledged. The bioavailability of As is impacted by a number of soil properties, such as pH, clay and metal concentrations. By retrieving 485 data from 32 publications, the aim of this study was to determine the relationship between selected metals (Fe and Al) and As bioavailability. In present study, the bioaccessibility (BAC) data measured by in vitro approaches were converted into bioavailability data based on the previously determined relationship between BAC and bioavailability. The As relative bioavailability (RBA) was summarized to be 24.36 &plusmn; 18.49%, which is in the range previously reported. A significant association between Fe concentration and the bioavailability of As was observed while this association varied for different types of RBA data. This disparity may suggest a non-reliable association between Fe and As bioavailability. The correlations between logarithmically transformed total content of Fe + Al and As bioavailability is then outlined: RBA = (&minus;8.40 &plusmn; 1.02) &times; Ln(Fe + Al) + (58.25 &plusmn; 4.09), R² = 0.25, p < 0.001, n = 212. Jackknife resampling was also applied to validate the relation between total content of (Fe + Al) and As bioavailability, which suggested that the relation is robust. This is the first pooled study to address the relations between selected metal concentrations and As bioavailability, which may provide some implications to establish soil properties-based RBA prediction for As.Entities:
Keywords: arsenic; bioavailability; pooled study; soil properties
Mesh:
Substances:
Year: 2018 PMID: 29710849 PMCID: PMC5981927 DOI: 10.3390/ijerph15050888
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Summarized in vitro-in vivo relations for arsenic [5,18,19].
| Methods | RBA Measurement | Equations (% for RBA and BAC) |
|---|---|---|
| SBRC-G | AUC/blood | RBA = 0.99 × BAC + 1.89, R2 = 0.92 |
| IVG-G | AUC/blood | RBA = 0.89 × BAC + 5.14, R2 = 0.69 |
| PBET-G | AUC/blood | RBA = 0.60 × BAC + 10.20, R2 = 0.59 |
| UBM-G | AUC/blood | RBA = 0.99 × BAC + 0.80, R2 = 0.52 |
RBA: relative bioavailability; BAC: Bioavailability and bioaccessibility; AUC: the area under the curve.
Summarized Information for Model Descriptors.
| Independent Variables | Range | Mean ± Std | Median | Study Number | Data Number |
|---|---|---|---|---|---|
| As (mg/kg) | 4.4–310,000 | 3180 ± 18,841 | 268 | 30 | 462 |
| Fe (g/kg) | 2.09–317 | 53.14 ± 63.46 | 29.96 | 17 | 261 |
| Al (g/kg) | 0.67–98.9 | 23.79 ± 21.58 | 15.15 | 11 | 214 |
| P (mg/kg) | 4–8159 | 1057 ± 1401 | 550 | 8 | 154 |
| pH | 2.1–9 | 6.75 ± 1.55 | 7 | 18 | 280 |
| (Fe + Al) (g/kg) | 9.3–328.7 | 79.13 ± 72.61 | 51.44 | 11 | 212 |
| (Fe + Al)/As | 12.15–4807 | 754.99 ± 1134 | 225.88 | 10 | 197 |
| (Fe + Al)/(As + P) | 5.27–259.7 | 59.44 ± 55.6 | 37.50 | 6 | 145 |
Regressions for relation between selected metals and arsenic bioavailability.
| ID | Independent Variables | Data Type | Equations |
|---|---|---|---|
| 1 | Ln(As) (mg/kg) | RBA (in vivo) | Y = (−4.12 ± 1.02) × X + (48.85 ± 6.12), R2 = 0.07, |
| RBA (in vitro) * | Y = (0.18 ± 0.47) × X + (20.06 ± 2.45), R2 = 0.0006, | ||
| Combined | Y = (−0.27 ± 0.42) × X + (24.43 ± 2.37), R2 = 0.0009, | ||
| 2 | Ln(Fe) (g/kg) | RBA (in vivo) | Y = (−10.35 ± 1.53) × X + (62.2 ± 5.86), R2 = 0.27, |
| RBA (in vitro) * | Y = (−4.81 ± 1.22) × X + (41.22 ± 3.85), R2 = 0.11, | ||
| Combined | Y = (−6.99 ± 1.02) × X + (49.02 ± 3.18), R2 = 0.19, | ||
| 3 | Ln(Al) (g/kg) | RBA (in vivo) | Y = (−0.26 ± 1.74) × X + (24.58 ± 5.01), R2 = 0.0002, |
| RBA (in vitro) * | Y = (−7.07 ± 1.11) × X + (45.95 ± 3.16), R2 = 0.30, | ||
| Combined | Y = (−3.17 ± 1.33) × X + (33.99 ± 8.22), R2 = 0.037, | ||
| 4 | Ln(P) (mg/kg) | RBA (in vivo) | Y = (1.57 ± 1.34) × X + (18.05 ± 8.22), R2 = 0.02, |
| RBA (in vitro) * | Y = (1.03 ± 0.91) × X + (21.55 ± 8.46), R2 = 0.007, | ||
| Combined | Y = (1.61 ± 1.12) × X + (18.02 ± 5.68), R2 = 0.02, | ||
| 5 | Ln(Fe + Al) (g/kg) | RBA (in vivo) | Y = (−11.85 ± 1.79) × X + (73.52 ± 7.59), R2 = 0.29, |
| RBA (in vitro) * | Y = (−6.58 ± 1.11) × X + (50.60 ± 4.12), R2 = 0.27, | ||
| Combined | Y = (−8.40 ± 1.02) × X + (58.25 ± 4.09), R2 = 0.25, | ||
| 6 | Ln(Fe + Al)/Ln(As) | RBA (in vivo) | Y = (29.60 ± 10.34) × X + (62.47 ± 7.07), R2 = 0.24, |
| RBA (in vitro) * | Y = (8.70 ± 2.57) × X + (17.67 ± 2.57), R2 = 0.13, | ||
| Combined | Y = (2.42 ± 1.94) × X + (19.95 ± 1.94), R2 = 0.06, | ||
| 7 | Ln(Fe + Al)/Ln(As + P) | RBA (in vivo) | Y = (−74.67 ± 10.64) × X + (69.17 ± 10.64), R2 = 0.22, |
| RBA (in vitro) * | Y = (−82.34 ± 6.09) × X + (71.32 ± 6.09), R2 = 0.40, | ||
| Combined | Y = (−20.38 ± 10.06) × X + (59.30 ± 10.06), R2 = 0.07, |
Note: * the RBA data was obtained based on BAC by using Equations from Table 1.
Figure 1The relation between arsenic (As) concentration (con.) and its relative bioavailability (RBA).
Figure 2The relation between iron (Fe) concentration (con.) and arsenic relative bioavailability (RBA).
Figure 3The relation between total content of the iron (Fe) plus aluminium (Al) concentration (con.) and arsenic relative bioavailability (RBA).